Abstract:PURPOSE: Discovery and development of a novel anticancer PEG-SMR-Clu peptide to prevent breast cancer metastasis. How breast cancer cells and primary mammary epithelial cells interact and communicate with each other to promote tumorigenesis and how to prevent tumor metastasis has long been a concern of researchers. Cancer cells secrete exosomes containing proteins and RNA. These factors can influence tumor development by directly targeting cancer cells and tumor stroma. In this study, we determined the effects of a peptide as an inhibitor of exosome secretion on breast tumors. We developed a peptide derived from the Secretion Modification Region (SMR) of HIV-1 Nef protein that was modified with PEG on the N-terminus and with a Clusterin (Clu)-binding peptide on the C-terminus. Attachment of PEG to the SMR peptide, termed PEGylation, offers improved water solubility and stability as well as reduced clearance through the kidneys, leading to a longer circulation time. The 12-mer Clu-binding peptide plays multiple roles in tumor development and metastasis. The Clu peptide can be detected by antibody in vivo, thus it has the potential to be used to monitor tumor status and treatment efficacy in animal studies and eventually in cancer patients.RESULTS: PEG-SMRwt-Clu and PEG-SMRwt peptides inhibited the growth of both of MCF-7 (estrogen responsive, ER+) and MDA-MD-231 (estrogen non-responsive, ER-) human breast cancer cells in a dose and time-dependent manner, without inducing cytotoxic effects. The SMRwt peptide, combined with paclitaxel, induced G2/M phase cell cycle arrest on MCF-7 and MDA-MB-231 cells but did not promote apoptosis. PEG-SMRwt-Clu peptide treatment blocked exosome release from both MCF-7 and MDA-MB-231 cells. This effect was blocked by knockdown of the chaperone protein mortalin by either antibody or siRNA.MATERIALS AND METHODS: MCF-7 and MDA-MB-231 breast tumor cells were treated with PEG-SMR-Clu peptide alone and in combination with paclitaxel and cisplatin. Cell proliferation and viabilty were determined via cell cycle analysis using Cellometer imaging cytometry, Annexin V and MTT assays. The effects of the PEG-SMR-Clu peptide on tumor exosome release were determined by testing isolated exosome fractions, for (i) expression of CD63 and Alix proteins by Western blotting, (ii) NanoSight nanoparticle tracking analysis (NTA 10) to measure exosomes size and concentration, and (iii) measurement of acetylcholinesterase (AchE) for exosome specific enzyme activity.CONCLUSIONS: PEG-SMRwt-CLU peptides inhibited the growth of human breast cancer cells and blocked tumor exosome release in vitro. The peptide alone did not cause increased cytotoxicity or apoptosis induction, but did cause cell cycle G2/M phase arrest in both estrogen responsive and non-responsive breast cancer cells. These data suggest a potential therapeutic value of SMR to prevent breast cancer metastasis and as an adjuvant for the chemotherapeutic treatment of human breast cancer.

PEGylated conjugated linoleic acid stimulation of apoptosis via a p53-mediated signaling pathway in MCF-7 breast cancer cells

Pegylation of Conjugated Linoleic Acid and Its Application As an Anti-Cancer Prodrug

Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells.

Lipolysis is Stimulated by PEGylated Conjugated Linoleic Acid Through the Cyclic Adenosine Monophosphate-Independent Signaling Pathway in 3T3-L1 Cells: Activation of MEK/ERK MAPK Signaling Pathway and Hyper-Secretion of Adipo-Cytokines.

Multifunctional Nanoparticles Combining Host-Guest Interaction of Cb[7] and Auns for Light-Promoted Endosome Escape and High Gene Transfection

Epigenetic Modifications of Conjugate Linoleic Acid (CLA) on Tumor Suppressor Gene, Protein Tyrosine Phosphatase Γ (ptpγ), in MCF-7 Cells

Conjugated Linoleic Acid Induces Apoptosis Through Estrogen Receptor Alpha in Human Breast Tissue

Conjugated Linoleic Acid (CLA) Up-Regulates the Estrogen-Regulated Cancer Suppressor Gene, Protein Tyrosine Phosphatase Gamma (ptpgama), in Human Breast Cells.

Studies on PPAR gamma Signal Pathway of Conjugated Linoleic Acid Isomers Induce Apoptosis of Human Breast Cancer Cell Line SKBr3

Effects of Human Breast Stromal Cells on Conjugated Linoleic Acid (CLA) Modulated Vascular Endothelial Growth Factor-a (VEGF-A) Expression in MCF-7 Cells.

Conjugated Linoleic Acid (CLA) Modulates Prostaglandin E2 (PGE2) Signaling in Canine Mammary Cells.

Appraisal of the Possible Role of PPAR γ Upregulation by CLA of Probiotic Pediococcus pentosaceus GS4 in Colon Cancer Mitigation

Deguelin and Paclitaxel Loaded PEG-PCL Nano-Micelles for Suppressing the Proliferation and Inducing Apoptosis of Breast Cancer Cells

Dietary conjugated Linoleic acid modulation of phorbol ester skin tumor promotion

Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1

Potential Mechanism of Mycelium Polysaccharide from Pholiota Dinghuensis Bi in Regulating the Proliferation and Apoptosis of Human Breast Cancer MCF-7 Cells Through P38/mapk Pathway

Suberoyl Bis-Hydroxamic Acid Induces P53-Dependent Apoptosis of MCF-7 Breast Cancer Cells

ClpP regulates breast cancer cell proliferation, invasion and apoptosis by modulating the Src/PI3K/Akt signaling pathway

PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF)

Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells

20(S)-Protopanaxadiol-induced Apoptosis in MCF-7 Breast Cancer Cell Line Through the Inhibition of PI3K/AKT/mTOR Signaling Pathway